Novartis signs gene therapy deal with Voyager for $100 million upfront
The gene therapy developer would provide Novartis access to its RNA-based screening platform — which helps in rapid discovery of experimental gene therapies — and would also be eligible for tiered royalties on global sales of products developed using the platform. The companies would collaborate to develop a pre-clinical gene therapy candidate for Huntington's disease (HD), an inherited condition that causes nerve cells in parts of the brain to gradually break down and die. Voyager would advance the pre-clinical development and Novartis would be responsible for all clinica...
Source: yahoo.com
